SYN STOCK NEWS TRIAL

It is unclear right now based on current values. Although price has broken the lower band and a downside breakout is possible the most likely direction for is to continue within current trading range. has closed below the lower bollinger band by 11.0%. From the relationship between price and moving averages: This stock is BEARISH in short-term and BEARISH in mid-long term. Short-term moving average is currently below mid-term and below long-term moving average. Price has closed below its short-term moving average. Price, moving averages and Bollinger Bands Stoxline posted a SELL today, same as yesterday.

SYN STOCK NEWS TRIAL

Louis to conduct a Phase 1b/2a clinical trial of SYN-004. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center and a clinical trial agreement with Washington University School of Medicine in St. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics SYN-005 for the prevention and treatment of pertussis and VCN-11 to treat cancer.

It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.

Syn stock news